

thereof;

(B) , at least one essential lipid;

(C) at least one protective antioxidant lipid; and

(D) at least one compound selected from the group consisting of

mucopolysaccharide and collagen.

17. A method of treating congenital biliary atresia comprising administering the composition of claim 16 to a mammal in need thereof.

18. A method of treating a damaged tissue comprising administering the composition of claim 16 to a mammal in need thereof.

19. The composition of claim 16, wherein the at least one compound is a mucopolysaccharide.

20. The composition of claim 19 wherein the mucopolysaccharide is chondroitin sulfate.

21. The composition of claim 16, wherein the at least one protective antioxidant lipid is eicosopentanoic acid.

22. The composition of claim 16, wherein the at least one compound is collagen.

REMARKS

New claims 16-22 are supported at pages 10-11 and by the original claims. No new matter has been added.

Claim 12 is canceled without prejudice and claim 16 is added to avoid any confusion over whether collagen is properly characterized as a mucopolysaccharide. Although the specification discloses collagen as a type of mucopolysaccharide at page 11, such characterization may run counter to the understanding of one skilled in the art. Accordingly, to avoid confusion, the

SERIAL NO.: 09/639,859

5163*3

claims have been amended such that collagen is no longer a species of mucopolysaccharide.

Respectfully submitted,

CONNOLLY BOVE LODGE & HUTZ LLP

By Christine Hansen
Christine M. Hansen
Reg. No. 40,634
Tel. (302) 658-9141

:\ODMA\MHODMA\CB;119184;1

BEST AVAILABLE COPY